Jump to content

Brazikumab

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by AztecWarrior28 (talk | contribs) at 19:16, 7 February 2018 (add UNII). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Brazikumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetIL23
Clinical data
Other namesMEDI2070
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
FormulaC6410H9830N1718O2016S50
Molar mass144.8 kDa g·mol−1

Brazikumab (MEDI2070) (INN) is a human monoclonal antibody designed for the treatment of Crohn's disease.[1][2]

This drug was developed by MedImmune.

References

  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Brazikumab, American Medical Association.
  2. ^ World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 115" (PDF). WHO Drug Information. 30 (2).
Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Brazikumab&oldid=824503913"